The Lancet has just published findings from phase 3 of the trial for symptomatic myelofibrosis patients with anaemia.
The trial was titled MOMENTUM and is officially referred to as “Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study”
Interpretation of the trial results is that “Treatment with momelotinib, compared with danazol, resulted in clinically significant improvements in myelofibrosis-associated symptoms, anaemia measures, and spleen response, with favourable safety. These findings support the future use of momelotinib as an effective treatment in patients with myelofibrosis, especially in those with anaemia.”
Due to the paywall, it is not possible to provide the full study. but the summary is available HERE.